Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cell Therapeutics, Inc.
Oncology company announces approval of shares listing on Nuovo Mercato
January 14th, 2004
Cell Therapeutics, Inc., (CTI, CTIC) announced that Borsa Italiana S.p.A. has approved CTI's common stock for listing on the Nuovo Mercato in Italy. The listing of CTI's common stock on the Nuovo Mercato remains subject to the Commissione Nazionale per le Societa e la Borsa approving the publication by CTI of a listing prospectus relating to CTI's common stock, as well as CTI completing its proposed merger with Novuspharma S.p.A. (Novuspharma), a Bresso (Milan), Italy-based public biopharmaceutical company that is developing Pixantrone, a potentially less cardiotoxic, more active anthracycline in phase III clinical trial for lymphoma. The...
Source: Biotech Week (2004-01-14)
|
